Business Wire

Galderma Expands Restylane® Portfolio in Japan With Launch of OBT™ Hyaluronic Acid Injectables Restylane Defyne™ and Refyne™

11.2.2026 07:00:00 CET | Business Wire | Press release

Share

Restylane® Refyne™ and Restylane Defyne™ are the first Optimal Balance Technology (OBT™) hyaluronic acid injectables ever approved and launched in Japan, bringing advanced flexibility and natural movement to the market1,2 This expands Galderma’s Restylane portfolio in Japan to four products, enabling treatment of a wider spectrum of patient and practitioner needs3,4 These two new launches underscore Galderma’s accelerating growth across the Japan & Asia Pacific (JPAC) region

Galderma (SIX: GALD), the pure-play dermatology category leader, has announced the launch of Restylane Defyne and Restylane Refyne: the first OBT‑based hyaluronic acid injectables ever authorized in Japan.1,2 The products – designed for injection into the mid-to-deep dermis for the correction of moderate to severe facial wrinkles and folds – are now commercially available in the market.1,2

Restylane Defyne and Refyne leverage the unique balance of softness, flexibility, and support delivered by Galderma’s proprietary OBT – designed to move in harmony with facial expressions while maintaining shape and lift – and are the first and only hyaluronic acid injectables clinically proven to restore youthful facial expressions.1,2,5-11 Restylane Refyne offers a smooth, flexible gel, ideal for delicate, highly expressive areas, while Restylane Defyne provides support for areas such as the jawline and deeper facial folds.1,2,5-11 These launches mark a major milestone for Galderma and represent an important chapter in its JPAC growth strategy, supporting the company’s continuing expansion in one of the region’s most dynamic aesthetics markets.

 

“The introduction of OBT technology to Japan is a significant milestone not only for clinicians but for the region’s aesthetic landscape as a whole. By combining the power of both NASHA® and OBT within the Restylane portfolio in Japan, physicians can tailor treatments more precisely than ever before. This broader set of tools supports natural‑looking, expressive outcomes and aligns Japan with international best practice.”

 

DR. STEPHANIE LAM

PLASTIC SURGEON, CENTRAL HEALTH MEDICAL PRACTICE

HONG KONG

 

The Restylane portfolio in Japan now includes four products in total, with Refyne and Defyne joining NASHA-powered products, Restylane Classyc™ and Restylane Lyft™.1-4 This versatile range enables clinicians to meet diverse patient needs, from soft, flexible formulations that smooth fine lines, to firmer gels that deliver contouring and support.1-7,12,13

The approvals of Restylane Refyne and Defyne in Japan were based on two pivotal, double-blinded, randomized, active-controlled phase III studies investigating the products in 171 and 162 subjects, respectively. Restylane Refyne and Defyne met the studies’ endpoints, demonstrating a clinically meaningful improvement in wrinkle severity for up to 12 months, with most patients reporting at least a 1-grade improvement in self-assessment scores after six weeks.1,2

 

“The approval of Restylane Defyne and Refyne – the first OBT HA injectables ever authorized in Japan – is a landmark moment for Galderma in the region. A decade after NASHA’s introduction to this market, we are proud to now offer a fully rounded Restylane portfolio that gives healthcare professionals even more precision and flexibility to meet the needs of their patients. Japan is an important growth engine for our business, and this milestone underscores our long-term commitment to bringing world-leading aesthetic technologies to the region.”

 

HON KEONG CHOO

HEAD OF JPAC REGION

GALDERMA

 

With over 30 years of innovation and more than 77 million treatments administered worldwide, Restylane is highly relevant in addressing some of today’s most significant aesthetic trends and needs, from improving facial harmony following medication-driven weight loss to growing concerns around menopause-related skin health and aging.5,14-17 The arrival of OBT technology in Japan now aligns the market more closely with global Restylane availability, reinforcing the brand’s position as the world’s most scientifically studied and diverse hyaluronic acid injectables range.

About the Restylane portfolio
Restylane hyaluronic acid treatments are designed differently to go beyond volumizing for natural-looking results.4,5,18,19 Our hyaluronic acid is minimally modified and our innovative manufacturing process preserves its biocompatibility while creating individual products designed for a specific purpose.20-22 Powered by NASHA, NASHA HD™, OBT and SB-NASHA™ technologies, Restylane offers gels with the highest firmness to the highest flexibility, enabling personalized treatments that deliver structural support, natural-looking results, and a healthy glow.12,13,23,24 Trusted for almost three decades, our hyaluronic acid gels work in sync with your skin for 100% natural-looking results.5-7

About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References

  1. Restylane® Defyne™. IFU. Japan. Available online. Accessed February 2026
  2. Restylane® Refyne™. IFU. Japan. Available online. Accessed February 2026
  3. Restylane® Lyft™. IFU. Japan. Available online. Accessed February 2026
  4. Restylane® Classyc™. IFU. Japan. Available online. Accessed February 2026
  5. Di Gregorio C, et al. 25+ years of experience with the Restylane portfolio of injectable HA fillers for facial aesthetic treatment. E-poster presented at AMWC; March 27-29, 2024; Monaco
  6. Solish N, et al. Dynamics of HA fillers formulated to maintain natural facial expression. J Cosmet Dermatol. 2019;18(3):738-746. doi: 10.1111/jocd.12961
  7. Philipp‐Dormston WG, et al. Perceived naturalness of facial expression after HA filler injection in nasolabial folds and lower face. J Cosmet Dermatol. 2020;19(7):1600-1606. doi: 10.1111/jocd.13205
  8. Philipp‐Dormston WG, et al. Evaluating perceived naturalness of facial expression after fillers to the nasolabial folds and lower face with standardized video and photography. Dermatol Surg. 2018;44(6):826-832. doi: 10.1097/DSS.0000000000001419.
  9. Galderma. Data on file. MA-43049. xStrain and G’ Global HA filler rheology data. 2023
  10. Galderma. Data on file. MA-42769. Restylane Defyne Clinical study report. 2020
  11. Öhrlund Å. Evaluation of rheometry amplitude sweep cross-over point as an index of flexibility for HA fillers.JCDSA. 2018;8(2):47-54
  12. Galderma Data on file. MA-56724. X-strain and G’ including Shaype
  13. Öhrlund Å. Differentiation of NASHA and OBT hyaluronic acid gels according to strength, flexibility, and associated clinical significance.J Drugs Dermatol. 2014;23(1):1332-1336. doi: 10.36849/JDD.7648
  14. Galderma. Data on file. MA-57232 [Updated]. 77 Million treated. 2025
  15. Galderma. Data on file. MA-55607. Restylane® 27 years data publications analysis. 2023
  16. Fabi G, et al. The potential role of biostimulators/dermal fillers to address menopause-related skin conditions. Poster presented at IMCAS; January 29-31, 2026; Paris, France
  17. Lorenc ZP, et al. Synergistic efficacy and safety of poly-L-lactic acid biostimulator and hyaluronic acid filler for facial fullness post weight loss due to glucagon-like peptide-1 receptor agonist medication. Presented at the ASDS 2025 Annual Meeting; November 13-16; Chicago, United States
  18. Nikolis A, et al. The role of clinical examination in midface volume correction using hyaluronic acid fillers: should patients be stratified by skin thickness? Aesthet Surg J Open Forum. 2020;2(1):1–12. doi: 10.1093/asjof/ojaa005
  19. Talarico S, et al. High patient satisfaction of a HA filler producing enduring full-facial volume restoration: an 18- month open multicenter study. Dermatol Surg. 2015;41:1361–1369. doi: 10.1097/DSS.0000000000000549
  20. Edsman K, et al. Gel properties of hyaluronic acid dermal fillers. Dermatol Surg. 2012;38:1170–1179. doi: 10.1111/j.1524-4725.2012.02472.x.
  21. Galderma. Data on file. MA-58650. Degree of modification of HA fillers.
  22. Seo K. Facial volumization with fillers. Springer. 2021;29–83. doi: 10.1007/978-981-33-6212-3_2
  23. Nikolis A, et al. Effectiveness and safety of a new hyaluronic acid injectable for augmentation and correction of chin retrusion. J Drugs Dermatol. 2024;23(4):255–261. doi: 10.36849/JDD.8145
  24. Belmontesi M et al. Injectable non-animal stabilized hyaluronic acid as a skin quality booster: an expert panel consensus. J Drugs Dermatol. 2018;17(1):83–88.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260210555523/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 01:01:00 CEST | Press release

Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F

FDA Authorizes ZYN ULTRA Nicotine Pouches Following Scientific Review21.8.2026 21:11:00 CEST | Press release

Authorizations add selection of ZYN ULTRA products to PMI U.S.’s growing portfolio of better alternatives for legal-age adults who smoke or use traditional oral tobacco products Philip Morris International Inc. (NYSE: PM) today announces that the U.S. Food and Drug Administration (FDA) issued Marketing Granted Orders to PMI’s U.S. affiliate, Swedish Match USA, Inc., authorizing the marketing of 11 ZYN ULTRA moist oral nicotine pouch products, including all 9mg variants and one 11mg variant. Additional 11mg variants remain under scientific review. Today’s action further enhances PMI’s leadership role in the smoke-free category. “We are delighted with the FDA’s decision to authorize a range of ZYN ULTRA products, which will build on ZYN’s position as America’s leading smoke-free product brand,” said Stacey Kennedy, PMI U.S. CEO. “We look forward to expanding our portfolio of better choices for the 45 million Americans who consume nicotine products.” ZYN ULTRA positions the brand to furth

58% of Consumers Say They Don't Care Whether a Product is a National Brand or Private Label. They Just Buy What They Need21.8.2026 12:00:00 CEST | Press release

New NIQ & World Data Lab report reveals how consumer polarization is redefining value, accelerating private label adoption, and reshaping competition on the shelf As fast-moving consumer goods (FMCG) prices rose 26% globally between 2021 and 2025, consumers have become more deliberate about where they save and where they spend. NielsenIQ (NYSE: NIQ) has released new findings showing that private label is no longer viewed simply as a lower-cost substitute, but as a credible competitor across value, mainstream, and premium segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260819950224/en/ Private label is no longer just a value play. The findings, published in NIQ’s latest report, A Tale of Two Consumers: The Polarized Mindsets Reshaping Global Consumption, created in collaboration with World Data Lab, show how consumer polarization is redefining value and reshaping competition on the shelf. The report also draws on ins

Tanium Reappoints Co-Founder Orion Hindawi as CEO to Drive Next Chapter of Growth20.8.2026 21:10:00 CEST | Press release

Company to focus on deepening its Autonomous IT capabilities, further expanding AI offerings across its portfolio, and strengthening customer and partner engagement Tanium, a leader in Autonomous IT, today announced that Co-Founder and Executive Chairman Orion Hindawi has been appointed Chief Executive Officer, effective immediately. Dan Streetman is stepping down as CEO and as a member of the Board after leading Tanium for the last three years, during which time Tanium scaled its go-to-market operations and secured strong industry analyst recognition for innovation within the Tanium platform. Streetman will continue to advise Tanium as part of the transition and co-founder David Hindawi will return to the role of Chairman of the Board. With this foundation in place, this transition positions Tanium to deepen its Autonomous IT capabilities and further expand AI offerings across its portfolio and strengthen customer and partner engagement. The Hindawis co-founded Tanium in 2007 to build

PCI Energy Solutions to Join Mitsubishi Electric, Reinforcing Long-Term Commitment to Customers, Employees, and the Energy Industry20.8.2026 19:46:00 CEST | Press release

Mitsubishi Electric to retain PCI’s core management team and support continuity of operations, customer service, and product innovation PCI Energy Solutions ("PCI"), a leading U.S.-based provider of enterprise software for energy management and optimization, announced today that it has entered into a definitive agreement to be acquired by Mitsubishi Electric Corporation. The agreement was executed on August 20, 2026 (Japan Standard Time). The Transaction represents a strong endorsement of PCI's business, technology, employees, customer relationships and position in the energy industry. Mitsubishi Electric intends to retain PCI's core management team following completion of the Transaction, enabling PCI to preserve leadership continuity, industry expertise and its customer-focused operating model while benefiting from Mitsubishi Electric's global scale, complementary capabilities and long-term investment capacity. The agreement has been signed, but the Transaction has not yet closed. PC

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye